Previous 10 | Next 10 |
The government's $2 trillion emergency relief package caused shares to skyrocket this week; however, the helicopter-Ben style package may inadequately address mid-term economic instability. If so, then this week's rapid run-up could be a short-term sugar high that wears off in April once disma...
Plenty of stocks have cratered in recent weeks as COVID-19 overtook headlines and our way of life. However, amid the coronavirus chaos, buying opportunities have emerged for those bold enough to act. Here are three drug stocks that could provide a handsome payoff. Image source: Gett...
Last week, I wrote "it's time to take a step back, breathe deep, and objectively identify money-making opportunities," and I reminded investors that "if you were in cash during the top 10 best days in the stock market over the past 20 years, then your overall return is half what it would've ...
Verastem (NASDAQ: VSTM ): Q4 Non-GAAP EPS of -$0.40 misses by $0.01 ; GAAP EPS of -$0.51. More news on: Verastem, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today reported financial results for the three months and full-year ended December 31, 2019, and provided an over...
Gainers: iBio (NYSEMKT: IBIO ) +181% . More news on: iBio, Inc., Dynatronics Corporation, Altimmune, Inc., Stocks on the move, , Read more ...
Dynatronics (NASDAQ: DYNT ) +224% . More news on: Dynatronics Corporation, Altimmune, Inc., Allied Healthcare Products, Inc., Stocks on the move, , Read more ...
Verastem (NASDAQ: VSTM ) has announced a new strategic direction to accelerate the advancement of its clinical development programs. More news on: Verastem, Inc., Healthcare stocks news, Read more ...
Verastem (NASDAQ: VSTM ) has agreed to sell approx. 46.5M common shares to certain institutional investors in a private placement, at $2.15 per share, for expected gross proceeds of ~$100M. More news on: Verastem, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Transformative Initiative Expected to Accelerate Development of CH5126766 (VS-6766), a RAF/MEK Inhibitor, in Combination with Defactinib, a FAK Inhibitor, for the Treatment of KRAS Mutant Solid Tumors Company Continues to Advance Development of Duvelisib for the Treatment of Relapsed/R...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock and accompanying warrants to purchase up to 13,333,334 shares of it...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock, as well as pre-funded warrants t...